Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10204303 | 0.90 | SMN1; SMN2 (0.34) | CYP1A2CYP3A4CYP2D6CA2CA9 | |
| SCHEMBL31039395 | 0.84 | PTGS2 (0.36) | ALDH1A1KDM4EUSP2LMNARORC | |
| SCHEMBL18731838 | 0.82 | S1PR2 (0.35) | S1PR2BCHEACHETACR1SLC6A4 | |
| SCHEMBL4426073 | 0.80 | IDO1 (0.48) | TACR1CA2CA9ALDH1A1KDM4E | |
| SCHEMBL5793683 | 0.79 | RECQL (0.49) | CYP3A4CA2CA9LMNACA1 | |
| SCHEMBL1312907 | 0.78 | CA2 (0.36) | CYP1A2CYP3A4CYP2D6CA2CA9 | |
| SCHEMBL17859838 | 0.78 | KMT2A (0.47) | CYP1A2CYP3A4CYP2D6ALDH1A1LMNA | |
| SCHEMBL10204294 | 0.77 | CYP1A2 (0.34) | CYP1A2CYP3A4CYP2D6CA2CA9 | |
| SCHEMBL16533093 | 0.77 | PTGS2 (0.40) | PTGS2 | |
| SCHEMBL19534275 | 0.77 | ALDH1A1 (0.35) | CYP1A2CYP3A4CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| EP-3601253-B1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AG (DE) | 2021-09-15 | — | — | EP | disclosed |
| US-7807694-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1752455-A2 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2007-02-14 | — | — | EP | disclosed |
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-11-09 | — | — | US | disclosed |
| US-7091217-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-08-15 | — | — | US | disclosed |
| EP-1317451-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-08-09 | — | — | EP | disclosed |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-6734191-B2 | PREFERABLY TERTIARY AMINES COMPRISING TETRAHYDROQUINOLINE AND BENZIMIDAZOLE; USE TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND FELINE IMMUNODEFICIENCY VIRUS (FIV) | ANORMED, INC. (CA) | 2004-05-11 | — | — | US | disclosed |
| EP-1317451-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-02-06 | — | — | US | disclosed |
| WO-2002034745-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | S1PR2 3325/4885CYP1A2 1918/4885CYP3A4 2151/4885 |
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | S1PR2 3190/4885CYP1A2 2250/4885CYP3A4 2923/4885 |
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | S1PR2 171/4885CYP1A2 3241/4885CYP3A4 1669/4885 |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | S1PR2 171/4885CYP1A2 3241/4885CYP3A4 1669/4885 |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | S1PR2 171/4885CYP1A2 3241/4885CYP3A4 1669/4885 |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | S1PR2 3014/4885CYP1A2 1043/4885CYP3A4 1166/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | S1PR2 3190/4885CYP1A2 2250/4885CYP3A4 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.